文献速递胸部肿瘤支持与姑息治疗

电子鼻预测恶性间皮瘤免疫检查点抑制剂治疗反应

Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
PubMed 文献 · Eur J Cancer · 2021-06-01

这项概念验证前瞻性观察研究纳入31例复发恶性胸膜间皮瘤患者,在接受纳武利尤单抗联合伊匹木单抗治疗前及治疗6周时用电子鼻采集呼气谱,6个月随访时按改良RECIST评估疗效。

要点

  • 基线电子鼻呼气谱可区分纳武利尤单抗联合伊匹木单抗的应答者与非应答者。
  • 该概念验证结果提示电子鼻可能用于筛选ICI治疗获益亚组。

核心结论

  • 电子鼻可在基线区分恶性胸膜间皮瘤患者对纳武利尤单抗联合伊匹木单抗治疗是否应答。

研究设计与样本

  • 该研究为前瞻性观察性概念验证研究,嵌套于INITIATE干预研究,纳入接受纳武利尤单抗联合伊匹木单抗治疗的复发恶性胸膜间皮瘤患者。
  • 基线及治疗6周时用电子鼻采集呼气谱,6个月随访时采用改良RECIST评估疗效。
  • 基线呼气数据可分析的患者共31例,其中治疗6个月后应答16例、非应答15例。

主要发现

  • 基线呼气谱在应答者与非应答者之间差异显著,交叉验证值为71%。

关键数值与推荐

  • 疗效评估采用改良RECIST,评估时点为6个月随访。

临床怎么用

  • 电子鼻呼气分析有望在治疗前识别更可能从纳武利尤单抗联合伊匹木单抗获益的恶性胸膜间皮瘤患者。
  • 该结果尚属概念验证,临床常规使用前需进一步外部验证。

局限性

  • 研究为概念验证性小样本观察性研究,基线可分析呼气数据仅31例。
  • ROC-AUC基于内部交叉验证,未报告外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent clinical trials with immune checkpoint inhibitors (ICIs) have shown that a subgroup of patients with malignant pleural mesothelioma (MPM) could benefit from these agents. However, there are no accurate biomarkers to predict who will respond. The aim of this study was to assess the accuracy of exhaled breath analysis using electronic technology (eNose) for discriminating between responders to ICI and non-responders. METHODS: This proof-of-concept prospective observational study was part of an intervention study (INITIATE) in patients with recurrent MPM who were treated with nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4). At baseline and after six weeks of treatment, breath profiles were collected by an eNose. Modified Response Evaluation Criteria in Solid Tumors were used to assess efficacy at 6-month follow-up. For data processing and statistics, we used independent t-test analyses followed by linear discriminant and receiver-operating characteristic (ROC) analysis. RESULTS: Exhaled breath data of 31 MPM patients who received nivolumab plus ipilimumab were available at baseline. There were 16 with and 15 without a response after 6 months of treatment. At baseline, breath profiles significantly differed between responders and non-responders, with a cross validation value of 71%. The ROC-AUC after internal cross-validation was 0.90 (confidence interval: 0.80-1.00). CONCLUSION: An eNose is able to discriminate at baseline between responders and non-responders to nivolumab plus ipilimumab in MPM, thereby potentially identifying a subgroup of patients that will benefit from ICI treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Disselhorst MJ, de Vries R, Quispel-Janssen J, et al. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment. Eur J Cancer. 2021. PMID: 34087572. doi:10.1016/j.ejca.2021.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。